Innovative Blood Test Enables Early Detection of Multiple Cancers via Cell-Free DNA
A novel blood test utilizing cell-free DNA analysis offers high accuracy in detecting multiple cancer types early, promising to improve diagnosis and treatment outcomes.
A groundbreaking blood test developed by researchers from Geneseeq and Chinese medical institutions offers a promising noninvasive method for detecting various cancers at early stages. Utilizing advanced whole-genome sequencing and machine learning, this multi-cancer early detection (MCED) test analyzes cell-free DNA (cfDNA) fragments circulating in the bloodstream, which tumors shed into the blood.
In validation studies, the test demonstrated high accuracy, with an 87.4% sensitivity and 97.8% specificity in identifying cancer among a diverse cohort. It successfully predicted the tissue of origin in approximately 83% of cases, supporting its potential utility in guiding clinical decisions.
The study, published in Nature Medicine, involved a retrospective training phase with thousands of cancer patients and controls, followed by validation using independent cohorts. Ultimately, a prospective analysis enrolled nearly 3,700 asymptomatic individuals in China, where 43 cancer cases were identified within a year.
The test performed particularly well for cancers often diagnosed late, such as liver, ovarian, pancreatic, and lung cancers, with sensitivities ranging from 76.9% to 100%. Its ability to detect cancers early and accurately determine their origin could significantly improve early intervention and treatment outcomes.
By leveraging features like cfDNA fragment size, methylation patterns, copy number variations, and nucleosome positioning, the machine learning models achieved robust performance, even for early-stage tumors. The researchers suggest that this MCED test has the potential to transform cancer detection, enabling timely diagnosis and personalized treatment strategies.
This innovative approach represents a significant advancement in cancer screening, especially for cancers lacking effective routine screening methods. Further clinical trials and regulatory evaluations are underway to facilitate its integration into routine healthcare.
Source: https://medicalxpress.com/news/2025-06-blood-multiple-cancer-cell-free.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Elite Soccer Players Excel in Precision Trapping Techniques to Maintain Momentum
A new study reveals techniques used by elite soccer players to perform precise ball-trapping maneuvers, enabling smooth directional changes and improved ball control during gameplay.
Genetic Variants Offer Insights into Why Obesity Affects Individuals Differently
Genetic differences play a significant role in why obesity affects individuals differently, influencing health outcomes and paving the way for personalized treatment approaches.
Low Cervical Cancer Screening Rates in Counties Linked to Higher Incidence and Mortality
Counties with persistently low cervical cancer screening rates face significantly higher rates of diagnosis and death. This study highlights the urgent need for improved screening access in underserved areas to reduce cervical cancer burden.
Recall of Freeze-Dried Fruit from Sam's Club Due to Listeria Contamination
Sam's Club has recalled certain batches of freeze-dried fruit due to potential Listeria contamination, urging consumers to discard or return affected products for safety.